Media headlines about New England Nuclear (NASDAQ:LNTH) have been trending somewhat positive this week, according to Accern. The research group identifies positive and negative news coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. New England Nuclear earned a media sentiment score of 0.23 on Accern’s scale. Accern also assigned press coverage about the medical equipment provider an impact score of 46.3281903802417 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Here are some of the news stories that may have effected Accern Sentiment Analysis’s analysis:
LNTH traded down $0.75 during trading on Friday, reaching $15.35. The company had a trading volume of 198,559 shares, compared to its average volume of 397,235. The company has a debt-to-equity ratio of 11.40, a quick ratio of 2.60 and a current ratio of 3.16. New England Nuclear has a 12 month low of $10.65 and a 12 month high of $24.45. The firm has a market cap of $609.56, a P/E ratio of 15.35, a PEG ratio of 1.28 and a beta of 1.52.
New England Nuclear (NASDAQ:LNTH) last announced its quarterly earnings results on Monday, February 26th. The medical equipment provider reported $0.12 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.20 by ($0.08). New England Nuclear had a net margin of 37.23% and a negative return on equity of 68.13%. The company had revenue of $81.24 million during the quarter, compared to the consensus estimate of $78.57 million. During the same period in the previous year, the firm posted $0.18 EPS. The business’s quarterly revenue was up 9.3% compared to the same quarter last year. sell-side analysts anticipate that New England Nuclear will post 1.04 earnings per share for the current fiscal year.
A number of research analysts recently issued reports on LNTH shares. BidaskClub cut shares of New England Nuclear from a “buy” rating to a “hold” rating in a report on Tuesday, December 19th. Zacks Investment Research upgraded shares of New England Nuclear from a “hold” rating to a “buy” rating and set a $23.00 price objective for the company in a report on Wednesday, January 3rd. Finally, ValuEngine raised shares of New England Nuclear from a “hold” rating to a “buy” rating in a research note on Saturday, February 3rd. One analyst has rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the company’s stock. New England Nuclear presently has an average rating of “Hold” and an average target price of $24.75.
In other news, insider Michael P. Duffy sold 21,655 shares of the business’s stock in a transaction on Wednesday, January 10th. The shares were sold at an average price of $22.40, for a total value of $485,072.00. Following the sale, the insider now owns 156,784 shares of the company’s stock, valued at $3,511,961.60. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, SVP Timothy G. Healey sold 3,696 shares of the business’s stock in a transaction on Monday, February 26th. The stock was sold at an average price of $19.58, for a total transaction of $72,367.68. Following the completion of the sale, the senior vice president now directly owns 64,582 shares in the company, valued at approximately $1,264,515.56. The disclosure for this sale can be found here. In the last ninety days, insiders sold 68,022 shares of company stock worth $1,257,024. Insiders own 1.20% of the company’s stock.
TRADEMARK VIOLATION WARNING: “New England Nuclear (LNTH) Receiving Somewhat Favorable News Coverage, Analysis Shows” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright law. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2018/04/07/new-england-nuclear-lnth-receiving-somewhat-favorable-news-coverage-analysis-shows.html.
About New England Nuclear
Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, an ultrasound contrast agent used in ultrasound exams of the heart; TechneLite, a technetium generator that provides the essential nuclear material used in nuclear medicine procedures; and Xenon, a radiopharmaceutical gas used to assess pulmonary function and imaging cerebral blood flow.
Receive News & Ratings for New England Nuclear Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for New England Nuclear and related companies with MarketBeat.com's FREE daily email newsletter.